After FDA Approves Bone Disease Drug, Ultragenyx Sets $200K Price

After FDA Approves Bone Disease Drug, Ultragenyx Sets $200K Price

Source: 
Xconomy
snippet: 

Patients who have rickets experience a softening and weakening of their bones traced to a vitamin deficiency. In a rare, inherited form of the disease, vitamin D supplements don’t work.

Ultragenyx (NASDAQ: RARE) has received FDA approval for a drug to treat patients who have this form of the disease, called X-linked hypophosphatemia (XLH).